Study Details

Open

Reduced Dose of Cyclophosphamide to Prevent Graft versus Host Disease after Stem Cell Transplant

Cyclophosphamide is a chemotherapy (chemo) drug often given after a transplant to prevent GvHD. We are doing this study to see if a lower dose of cyclophosphamide after transplant is safer, but just as effective. Cyclophosphamide can prevent GvHD, but it can also make you sick and more likely to get an infection. This study will look at how well a lower dose of cyclophosphamide works to reduce these side effects, while also preventing GvHD. This study does not include any new or untested drugs. The drugs and procedures in this study are standard for transplant.

Age & Gender

18 years ~ 65 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

You will come to clinic to meet with your physician to discuss the study. If you are interested, you will sign the study consent form. The clinic team will run some test to see if you are eligible for the study. If you are eligible, your physician will assign you to a treatment arm based on your disease and best treatment. You will then receive chemotherapy with or without radiation to prepare your body for transplant. After your transplant, you will receive a reduced dose of cyclophosphamide to prevent Graft versus Host Disease. You will then come back to the clinic until one year after your transplant.

Incentives

You will receive $20.00 for each survey that you complete

In-person visits:
9

Total length of participation:
1 year after transplant

Looking for Specific Volunteers

Able to participate:

You have one of the following diseases: AML, ALL, MDS, CML, Myelofibrosis, CLL, or other leukemias and lymphomas that are chemosensitive at time of transplant
Available partially HLA-Mis-Matched Unrelated Donor for transplant

Not eligible if:

Suitable HLA-matched related or 8/8 high-resolution matched unrelated donor available
You have had a prior allogeneic transplant
You have had an autologous transplant within the past 3 months
You have uncontrolled bacterial, viral, or fungal infection at the time of the transplant preparative regimen

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Janell Markey
janell_markey@med.unc.edu

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Katarzyna Jamieson
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia, Lymphoma)
Transplant

IRB Number

23-2527

ClinicalTrials.gov

NCT06001385